Patients who have had systemic anticancer therapy (e.g., chemotherapy, targeted therapy) within  weeks prior to entering the study
Patients must have discontinued active immunotherapy (interleukin [IL]-, interferon, cytotoxic T-lymphocyte-associated protein  [CTLA-], etc.) or chemotherapy at least  weeks prior to entering the study and oral targeted therapy at least  weeks prior to entering the study; patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry
Patients must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study (except alopecia).
Participants must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study
There are no limits on prior lines of therapy; however, patients must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study (except alopecia)
Patients who have had chemotherapy or other systemic therapy or radiotherapy or patients who have not recovered from adverse events due to prior administered agents as follows:\r\n* Chemotherapy <  weeks prior to entering the study\r\n* Radiotherapy <  weeks prior to entering the study\r\n* Nitrosoureas/mitomycin C <  weeks prior to entering the study\r\n* Targeted therapy <  weeks (or  half-lives, whichever is longer) prior to entering the study\r\n* Those who have not recovered from clinically significant adverse events due to prior agents administered to grade =<  or baseline, with exception of alopecia and peripheral neuropathy, unless approved by the protocol chair
EXCLUSION - INFUSION: Currently receiving any investigational agents or radiotherapy within  weeks prior to entering the study
Patients must have received prior radiation therapy and/or chemotherapy and recovered from the acute treatment related toxicities (defined as =< grade  if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study; there is no upper limit to the number of prior therapies that is allowed
Patients must have received no more than  prior chemotherapy regimens and/or focal radiotherapy for their brain tumor and fully recovered from the acute treatment related toxicities of all prior therapies prior to entering this study; for those acute baseline adverse events attributable to prior therapy, patients must meet organ function criteria
Prior treatment with lenalidomide within  weeks prior to entering the study
Patients who have had chemotherapy or radiotherapy prior to entering the study must have recovered from adverse events to grade 
Patients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait  weeks prior to entering the study
Patients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait  weeks prior to entering the study; for recent experimental therapies a  day period of time must elapse before treatment
Patients who have had previous chemotherapy or radiotherapy for pancreatic adenocarcinoma prior to entering the study
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study
Chemotherapy or radiotherapy within  weeks prior to entering the study or those with residual treatment related toxicity of greater than grade  not addressed in inclusion criteria
Patients who have had chemotherapy, cytotoxic therapy, immunotherapy within  weeks prior to entering the study ( weeks for nitrosoureas), surgical resection within  weeks prior to entering the study, or have received experimental viral therapy or gene therapy at any time (e.g., adenovirus, retrovirus or herpes virus protocol); however, this does not preclude re-treatment with M at a later date
Subjects who have had chemotherapy within  weeks prior to entering the study
Patients who have been treated with hypomethylating agents prior to entering the study are eligible
Patients with clinically significant unexplained bleeding within  days prior to entering the study
Patients must have recovered from the acute treatment related toxicities (defined as =< grade ) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
Chemotherapy, targeted therapy, biologic or hormonal agents within  weeks prior to entering the study
Radiation therapy within  weeks prior to entering the study
Patients who have had anti-cancer therapy within  weeks prior to entering the study
Patients who have had chemotherapy or radiotherapy  weeks or more prior to entering the study whos adverse events have not recovered to grade  or less with the exception of alopecia and neuropathy
Patients must have completed chemotherapy, biological or radiotherapy >=  weeks prior to entering the study
Patients who have had radiotherapy within  days prior to entering the study
Patients who have had cytotoxic chemotherapy, radiotherapy, interferon (IFN), or ipilimumab before entering the study
Have had chemotherapy or radiotherapy within  weeks prior to entering the study
No prior chemotherapy or radiotherapy for the extra-ocular retinoblastoma may have been administered prior to entering this study; prior treatment (chemotherapy and/or radiation therapy) for intra-ocular retinoblastoma is permissible
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study
Radiotherapy within  weeks prior to entering the study
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered >  weeks prior to entering the study
Patients who have had any treatment for their CLL/SLL, including but not limited to chemotherapy, radiotherapy, or immunotherapy, prior to entering the study
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study are not eligible
Patients with clinically significant unexplained bleeding within  days prior to entering the study
Participants who have had chemotherapy or radiotherapy any time prior to entering the study or at any prior time for mesothelioma. Patients receiving chemotherapy type drugs for benign conditions can participate in this trial
Patients who have had radiation therapy within  week prior to entering the study
Patients must have discontinued active immunotherapy (interleukin [IL]-, interferon, cytotoxic T-lymphocyte antigen  [CTLA-], etc.) or chemotherapy at least  weeks prior to entering the study and oral targeted therapy at least  weeks prior to entering the study and have recovered from adverse events due to those agents; patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry, with the exception of vaccines
Patients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait  weeks prior to entering the study; for recent experimental therapies a  day period of time must elapse before treatment
Have had chemotherapy (including purine analogs, rituximab, and other investigational agents) within six weeks prior to entering the study
Patients who have had previous chemotherapy or radiotherapy for pancreatic adenocarcinoma prior to entering the study.
Patients who have had chemotherapy or radiotherapy to the reirradiation target within  weeks prior to entering the study
Patients with clinically significant unexplained bleeding within  days prior to entering the study
Patients with clinically significant unexplained bleeding within  days prior to entering the study
Surgery involving general anesthesia, radiotherapy, steroid therapy, or immunotherapy within  weeks prior to vaccination. Chemotherapy within  weeks prior to entering the study. Palliative radiotherapy is allowable. Collection of lumenal tissue for vaccine manufacture must be avoided.
Patients who have had chemotherapy or radiotherapy to the oropharynx prior to entering the study
Patients who have had chemotherapy, biologic therapy or radiotherapy within  weeks prior to entering the study
Previously undergone chemotherapy, brachytherapy, or radiotherapy prior to entering the study
Patients who have had radiotherapy within  months prior to entering the study or those who have not recovered to < grade  adverse events due to radiation
There are no limits on prior lines of therapy; however, patients must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study (except alopecia)
Patients who have had chemotherapy or radiotherapy within  weeks prior to entering the study or those who have not recovered from adverse events from prior treatments
Thiazide therapy within  days from entering the study
Patients who have had anti-cancer systemic therapy within  weeks prior to entering the study; radiation is allowed
Patients who have had chemotherapy (or so-called targeted systemic therapy), large field radiotherapy, or major surgery must wait  weeks after completing treatment prior to entering the study
Patients who have had palliative radiotherapy within  weeks prior to entering the study
Patients who have received any hormonal therapy directed at the malignancy within  weeks prior to entering the study
Any conventional molecularly targeted therapy within  weeks or, chemotherapy or radiotherapy within  weeks (local) or  weeks (systemic) prior to entering the study.
Patients who have had large field radiotherapy must wait  weeks prior to entering the study
Patients who have had chemotherapy (other than sorafenib treatment), large field radiotherapy, or major surgery must wait  weeks prior to entering the study
Patients with clinically significant unexplained bleeding within  days prior to entering the study
Participants who have had radiotherapy within  weeks prior to entering the study or those who have not recovered from gastrointestinal (GI) adverse events due to induction therapy; patients who have had localized radiation which would not result in any GI effects are allowed on study
Participants who have had surgery, chemotherapy, or radiotherapy of the sacrum prior to entering the study
Subjects who have had chemotherapy or radiotherapy within  week of entering the study
Patients who have had chemotherapy or other systemic therapy or radiotherapy, or those who have not recovered from adverse events due to prior administered agents as follows: chemotherapy, radiotherapy or surgery =<  weeks prior to entering the study, targeted therapy (e.g., TKI) =<  week prior to entering the study; autologous HSCT =<  weeks prior to entering the study; investigational drug or immunotherapy (e.g. rituximab) =<  weeks prior to entering the study; prophylactic intrathecal chemotherapy within one week of enrollment allowed; patients will be allowed to receive cytoreduction with hydroxyurea, -mercaptopurine, corticosteroids (dexamethasone, prednisone or similar) or cyclophosphamide provided that it is discontinued at least  hours prior to the initiation of study treatment; pre-phase treatment with dexamethasone  mg/m^ (maximum total  mg per day) for up to  days is required for patients with bone marrow blasts more than %, peripheral blood blasts of ,/uL or higher, or elevated lactate dehydrogenase suggesting rapidly progressing disease as per investigators assessment; pre-phase treatment must be stopped at least  hours prior to the initiation of blinatumomab
